menu
    • menu
    [{"orgOrder":0,"company":"RegeneRx Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"Thymosin Beta-4","moa":"Laminin-5 synthesis","graph1":"Ophthalmology","graph2":"Phase III","graph3":"RegeneRx Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"RegeneRx Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"RegeneRx Biopharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"RegeneRx Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Thymosin Beta-4","moa":"Angiopoietin-1","graph1":"Neurology","graph2":"Phase I","graph3":"RegeneRx Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"RegeneRx Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"RegeneRx Biopharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"RegeneRx Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Thymosin Beta-4","moa":"Laminin-5 synthesis","graph1":"Ophthalmology","graph2":"Phase III","graph3":"RegeneRx Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"RegeneRx Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"RegeneRx Biopharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"ReGenTree","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"Thymosin Beta-4","moa":"Laminin-5 synthesis","graph1":"Ophthalmology","graph2":"Phase III","graph3":"ReGenTree","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"ReGenTree \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"ReGenTree \/ Not Applicable"},{"orgOrder":0,"company":"GtreeBNT","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"Thymosin Beta-4","moa":"Laminin-5 synthesis","graph1":"Ophthalmology","graph2":"Phase III","graph3":"GtreeBNT","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"GtreeBNT \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"GtreeBNT \/ Not Applicable"},{"orgOrder":0,"company":"RegeneRx Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Thymosin Beta-4","moa":"Angiopoietin-1","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"RegeneRx Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"RegeneRx Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"RegeneRx Biopharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"RegeneRx Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"Thymosin Beta-4","moa":"Laminin-5 synthesis","graph1":"Ophthalmology","graph2":"Phase III","graph3":"RegeneRx Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"RegeneRx Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"RegeneRx Biopharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"ReGenTree","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"Thymosin Beta-4","moa":"Laminin-5 synthesis","graph1":"Ophthalmology","graph2":"Phase III","graph3":"ReGenTree","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"ReGenTree \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"ReGenTree \/ Not Applicable"},{"orgOrder":0,"company":"ReGenTree","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"Thymosin Beta-4","moa":"Laminin-5 synthesis","graph1":"Ophthalmology","graph2":"Phase III","graph3":"ReGenTree","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"ReGenTree \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"ReGenTree \/ Not Applicable"},{"orgOrder":0,"company":"RegeneRx Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"Thymosin Beta-4","moa":"Laminin-5 synthesis","graph1":"Ophthalmology","graph2":"Phase III","graph3":"RegeneRx Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"RegeneRx Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"RegeneRx Biopharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"RegeneRx Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"Thymosin Beta-4","moa":"Laminin-5 synthesis","graph1":"Ophthalmology","graph2":"Phase III","graph3":"RegeneRx Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"RegeneRx Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"RegeneRx Biopharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"RegeneRx Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"Thymosin Beta-4","moa":"Laminin-5 synthesis","graph1":"Ophthalmology","graph2":"Phase III","graph3":"RegeneRx Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"RegeneRx Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"RegeneRx Biopharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"RegeneRx Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"Thymosin Beta-4","moa":"Laminin-5 synthesis","graph1":"Ophthalmology","graph2":"Phase III","graph3":"RegeneRx Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"RegeneRx Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"RegeneRx Biopharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"RegeneRx Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"Thymosin Beta-4","moa":"Laminin-5 synthesis","graph1":"Ophthalmology","graph2":"Phase III","graph3":"RegeneRx Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"RegeneRx Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"RegeneRx Biopharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"ReGenTree","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"Thymosin Beta-4","moa":"Laminin-5 synthesis","graph1":"Ophthalmology","graph2":"Phase III","graph3":"ReGenTree","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"ReGenTree \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"ReGenTree \/ Not Applicable"},{"orgOrder":0,"company":"RegeneRx Biopharmaceuticals","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Peptide","year":"2021","type":"Private Placement","leadProduct":"Thymosin Beta-4","moa":"Laminin-5 synthesis","graph1":"Ophthalmology","graph2":"Phase III","graph3":"RegeneRx Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"RegeneRx Biopharmaceuticals \/ Roth Capital Partners","highestDevelopmentStatusID":"10","companyTruncated":"RegeneRx Biopharmaceuticals \/ Roth Capital Partners"},{"orgOrder":0,"company":"RegeneRx Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"Thymosin Beta-4","moa":"Laminin-5 synthesis","graph1":"Ophthalmology","graph2":"Phase III","graph3":"RegeneRx Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"RegeneRx Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"RegeneRx Biopharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"RegeneRx Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"Thymosin Beta-4","moa":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"RegeneRx Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"","sponsorNew":"RegeneRx Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"RegeneRx Biopharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"RegeneRx Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"Thymosin Beta-4","moa":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"RegeneRx Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"RegeneRx Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"RegeneRx Biopharmaceuticals \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Thymosin Beta-4

    Menu

    Thymosin Beta-4

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            RegeneRx Biopharmaceuticals

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            RegeneRx Biopharmaceuticals

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Thymosin Beta-4

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            First Patient Enrolled into U.S. Phase 3 Neurotrophic Keratitis Clinical Trial with RGN-259

                            Details : RGN-259 (Thymosin beta 4) is a sterile, preservative-free, eye drop developed to reduce damage and improve healing for various ophthalmic indications including dry eye syndrome and neurotrophic keratopathy.

                            Brand Name : RGN-259

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            April 13, 2023

                            Lead Product(s) : Thymosin Beta-4

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            RegeneRx Biopharmaceuticals

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            RegeneRx Biopharmaceuticals

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Thymosin Beta-4

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Publication of RGN-259 Phase 3 Clinical Trial Results in Patients with Neurotrophic Keratopathy

                            Details : RGN-259 (Thymosin beta 4) is a sterile, preservative-free, eye drop developed to reduce damage and improve healing for various ophthalmic indications including dry eye syndrome and neurotrophic keratopathy.

                            Brand Name : RGN-259

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            January 03, 2023

                            Lead Product(s) : Thymosin Beta-4

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            RegeneRx Biopharmaceuticals

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            RegeneRx Biopharmaceuticals

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Thymosin Beta-4

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            RegeneRx JV Updates RGN-259 Regulatory Progress for Dry Eye Syndrome

                            Details : RGN-259 represents a new approach to corneal healing, as there is currently no pharmaceutical agent that has shown corneal repair and anti-inflammatory properties.

                            Brand Name : RGN-259

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            July 14, 2021

                            Lead Product(s) : Thymosin Beta-4

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            RegeneRx Biopharmaceuticals

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            RegeneRx Biopharmaceuticals

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Thymosin Beta-4

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Sponsor : Roth Capital Partners

                            Deal Size : $2.0 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            RegeneRx Biopharmaceuticals, Inc. Closes $2 Million Private Placement

                            Details : RegeneRx drug candidate, RGN-259, is the subject of two Phase 3 clinical trials in the U.S. for patients with dry eye syndrome and neurotrophic keratopathy (an orphan indication). We expect the results of these trials to be available in 2020.

                            Brand Name : RGN-259

                            Molecule Type : Peptide

                            Upfront Cash : Undisclosed

                            July 01, 2021

                            Lead Product(s) : Thymosin Beta-4

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Sponsor : Roth Capital Partners

                            Deal Size : $2.0 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            ReGenTree

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            ReGenTree

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Thymosin Beta-4

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            RegeneRx Joint Venture Reports Positive Results from ARISE-3 Clinical Trial Using RGN-259 to Treat Dry Eye Syn...

                            Details : Completed analysis demonstrated a number of favorable efficacy parameters in ARISE-3 and, most importantly, numerous significant sign and symptom improvements with RGN-259 when pooling the patient data from all three phase 3 clinical trials.

                            Brand Name : RGN-259

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            May 14, 2021

                            Lead Product(s) : Thymosin Beta-4

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            RegeneRx Biopharmaceuticals

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            RegeneRx Biopharmaceuticals

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Thymosin Beta-4

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            RegeneRx Issues Update on ARISE-3 Trial

                            Details : The objective of this ARISE-3 Trial is to compare the safety and efficacy of RGN-259 Ophthalmic Solution to placebo for the treatment of the signs and symptoms of dry eye.

                            Brand Name : RGN-259

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            March 22, 2021

                            Lead Product(s) : Thymosin Beta-4

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            RegeneRx Biopharmaceuticals

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            RegeneRx Biopharmaceuticals

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Thymosin Beta-4

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            RegeneRx Reports Topline Results of ARISE-3 Dry Eye Trial

                            Details : The statistically significant improvement was seen at one and two weeks after treatment, and post-exposure in a controlled adverse environment after two weeks of treatment with RGN-259 compared to placebo (p=0.0104, 0.0307, and 0.0046, respectively).

                            Brand Name : RGN-259

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            March 18, 2021

                            Lead Product(s) : Thymosin Beta-4

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            RegeneRx Biopharmaceuticals

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            RegeneRx Biopharmaceuticals

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Thymosin Beta-4

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            RegeneRx Reports Topline Results of ARISE-3 Dry Eye Trial

                            Details : RGN-259 continued to demonstrate safety in treatment of dry eye syndrome consistent with previous clinical trials. In the ARISE-3 trial, there were no serious adverse events with only mild to moderate adverse events in both the active and placebo arms.

                            Brand Name : RGN-259

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            March 18, 2021

                            Lead Product(s) : Thymosin Beta-4

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            RegeneRx Biopharmaceuticals

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            RegeneRx Biopharmaceuticals

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Thymosin Beta-4

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            RegeneRx JV Locks Clinical Trial Database for Phase 3 Dry Eye Trial

                            Details : ARISE-3 Phase 3 clinical trial database evaluating RGN-259 eyedrops for the treatment of dry eye syndrome has been locked after collecting and verifying patient data from 20 U.S. clinical sites participating in the study.

                            Brand Name : RGN-259

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            February 24, 2021

                            Lead Product(s) : Thymosin Beta-4

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            RegeneRx Biopharmaceuticals

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            RegeneRx Biopharmaceuticals

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Thymosin Beta-4

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            RegeneRx Comments on ARISE-3 Clinical Trial

                            Details : RGN-259, the Company's ophthalmic eye drop, recently complete a phase 3 clinical trial for dry eye syndrome in the U.S. and is expected to report top line results for the ARISE-3 clinical trial in early 2021.

                            Brand Name : RGN-259

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            January 26, 2021

                            Lead Product(s) : Thymosin Beta-4

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth